Breaking News

Avaxia Names Research VP

March 26, 2013

Hartman brings 20 years of R&D experience

Deborah S. Hartman, Ph.D. has been appointed vice president of Research at Avaxia Biologics, Inc. Dr. Hartman is a scientist and senior executive with more than 20 years of experience leading international pharmaceutical R&D functions in multiple therapeutic areas.
Prior to joining the company, Dr. Hartman held a number of executive level roles at AstraZeneca, most recently as vice president of Projects in Innovative Medicines. Other positions included vice president of Respiratory & Inflammation Research UK and vice president of Lead Generation DECS, a global science and technology group supporting early-stage projects in eight disease areas across 12 R&D sites. Prior to joining AZ, Dr. Hartman spent seven years at Hoffmann-La Roche in Basel, Switzerland, as a project leader and principal scientist in nervous system diseases.
Barbara S. Fox, Ph.D., chief executive officer of Avaxia, said, “Debbie has a strong track record of delivering new drugs into the clinic and managing early clinical development. In addition to leading research efforts on AVX-470, Debbie will expand our pipeline of gut-targeted oral antibody therapeutics through internal efforts and external collaborations. I would also like to thank Dan Tracey, our former vice president, Research, for his many contributions to Avaxia and to wish him well in his retirement. We are grateful that Dan will continue to support Avaxia as a consultant.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity